Date: 2014-04-28
Type of information: Financing round
Company: Orca Pharmaceuticals (UK)
Investors: BioMotiv (USA - OH)
Amount: $1.3 million
Funding type: financing round
Planned used: Orca Pharmaceuticals is developing an oral drug to treat a range of autoimmune diseases, with psoriasis as the primary therapeutic target. Working with Evotec AG, the company has developed a series of potent and selective compounds with pharmaceutical properties that are amenable to clinical development. The additional investment will enable the company to select a clinical candidate optimised for activity on key pathogenic immune cells.
Others: * On April 28, 2014, Orca Pharmaceuticals, a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases, has announced a further investment of $1.3 million from BioMotiv, a drug development accelerator based in Cleveland, Ohio and affiliated with The Harrington Project. Founded in 2013, the company’s technology is based on intellectual
property developed in the laboratory of Professor Dan Littman of New York University, a world leader in Th17 cell immunology. Orca also has close ties with Oxford University immunologists who are playing a key role in identifying promising therapeutic indications and selecting an optimised development candidate.
Therapeutic area: Autoimmune diseases
